A Set Aside Diabetes Medication May Make a Huge Comeback

In the history of medical science there have been numerous medications that were designed for one purpose, yet found success treating something entirely different. This is true of the drug Viagra and it may be true of Fenofibrate (brand names include Antara, Fenoglide, Lipofen, Lofibra, TriCor, Triglide).

In the history of medical science there have been numerous medications that were designed for one purpose, yet found success treating something entirely different. This is true of the drug Viagra and it may be true of Fenofibrate (brand names include Antara, Fenoglide, Lipofen, Lofibra, TriCor, Triglide).

This drug was designed to prevent heart disease. Long-term research shows that it did not work effectively to take care of this issue in a preventative way. What this ultimately means for most drugs is they would be set aside and rarely prescribed. In most cases they are pulled from the shelves and discontinued. Fenofibrate may be making a comeback, but not as preventative medicine for heart disease.

Research based in Australia, New Zealand and Finland followed 9,795 patients and discovered that the use of Fenofibrate may actually be a potent drug that seems to significantly reduce the potential of amputations among Type 2 diabetics. This study was conducted over a five-year period.

Current statistics indicate about 10% of Type 2 diabetics will lose at least a part of a lower limb to amputation. Fenofibrate could reduce the instance of the need for invasive surgery and long-term rehabilitation.

The truth is this information was buried in a 2005 study that was designed to prove or disprove Fenofibrates ability to serve as a heart drug. When the results showed it did not, the study was set aside. A new look at this study revealed findings that had been overlooked because it was not the original intent of the study.

Some amputation risk groups saw as much as a 50% decline in amputations when compared to others who were not taking Fenofibrates. The Lancet journal interpreted these findings; “Treatment with fenofibrate was associated with a lower risk of amputations, particularly minor amputations without known large-vessel disease, probably through non-lipid mechanisms. These findings could lead to a change in standard treatment for the prevention of diabetes-related lower-limb amputations.” Patients at risk for a first time amputation saw a 36% decrease when using Fenofibrates.

The Lancet also reported, “Fenofibrate has previously been shown to reduce macrovascular and microvascular complications of type 2 diabetes.”

This report suggests that a drug that has already proven helpful to Type 2 diabetics may actually provide greater support and amputation prevention than originally thought.

Medical science has moved toward statin-based drugs to help patients prevent heart disease. Fenofibrates could realistically be used to provide new support it had not previously been given credit for when used in conjunctions with statins.

As medical science moves forward in learning how drugs interact with our bodies and work to provide support for greater health the onus will still remain on the topic of education. In many cases diabetes can be avoided, prevented or delayed by participating in a lifestyle alteration that includes understanding how food interacts with your body and why physical activity is important in the process of effective glucose control.

In many cases a less active lifestyle is the norm in the 21st century. It can take concentration and dedication to buck the normal trend of a sedentary lifestyle in order to embrace one that includes more activity and a healthier variety of food. The end result is almost always positive and can often be managed without drugs.

However, when a diabetes diagnosis is given you will need to consider the possibility of a medical regimen to help you reach goals in managed care. The effects will be even greater when you become an active partner in your own care.

The Metformin Connection: Dead Fish

If you thought your diabetic medication smelled like dead fish – you’re not alone. New research seeks to determine if the smell of the medication may actually contribute to a common side effect – nausea.

If you thought your diabetic medication smelled like dead fish – you’re not alone. New research seeks to determine if the smell of the medication may actually contribute to a common side effect – nausea.

The medication is known as Metformin, which WebMD describes as, “an oral drug commonly used to treat type 2 diabetes. [It] generally has few serious side effects, but gastrointestinal upset and nausea are common. Although these effects have been well documented in studies, researchers say one unique characteristic of the pills may have been overlooked as a potential cause of the nausea: their strong fishy odor.”

The generic equivalent of this drug is known as Glucophage. WebMD describes this diabetic drug. “Metformin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes (non-insulin-dependent diabetes). Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Metformin belongs to the class of drugs known as biguanides. It works by helping to restore your body’s proper response to the insulin you naturally produce, and by decreasing the amount of sugar that your liver makes and that your stomach/intestines absorb.”

So while this drug serves a great purpose in the control of diabetes it can be disheartening when the medication cannot be taken because of issues related to its odor.

No official documentation exists as to the number of diabetics who have stopped or refused to use Metformin because of its distinctive smell, however there is plenty of online evidence that individuals are staying away from the drug for this very reason.

In a recent report, published in the Annals of Internal Medicine, researchers describe, “two cases in which patients discontinued use of generic metformin because of what they described as the nauseating smell of the drug,” according to WebMD.

The odor of this drug has even been liked to, “old locker room sweat socks”. While it is not conducive to positive image the odor is only linked to the immediate release version of the prescribed drug.

If you have an issue with the smell of your metformin or glucophage you should inquire about the availability of “film-coated, extended-release formulation of metformin as an alternative.”

Doctors will benefit from your honesty about the drug. If you are nauseated because of the smell this information will have a different meaning for them than if you experience stomach upset as a side effect of prescribed use. By knowing the exact reason for your discomfort your physician may be able to provide a solution.

“First synthesized and found to reduce blood sugar in the 1920s, metformin was forgotten for the next two decades as research shifted to insulin and other anti-diabetic drugs. Interest in metformin was rekindled in the late 1940s after several reports that it could reduce blood sugar levels in people, and in 1957, French physician Jean Sterne published the first clinical trial of metformin as a treatment for diabetes. It was introduced to the United Kingdom in 1958, Canada in 1972, and the United States in 1995. Metformin is now believed to be the most widely prescribed anti-diabetic drug in the world; in the United States alone, more than 40 million prescriptions were filled in 2008 for its generic formulations.” (Source: Wikipedia)

Avandia Under Fire

What if you knew that by adding a diabetic drug to your daily medical regimen you increased your risk of heart failure by more than 50%? Would you take the drug? One California County is taking a drug company to court to seek the removal of the drug from circulation.

What if you knew that by adding a diabetic drug to your daily medical regimen you increased your risk of heart failure by more than 50%? Would you take the drug? One California County is taking a drug company to court to seek the removal of the drug from circulation.

According to VOAnews, “The [Santa Clara County] lawsuit was spurred by a report on the drug released by the U.S. Senate … That report accused the drug company of withholding information about side effects of serious heart problems, including death.  At issue now is whether Avandia should be taken off the market.”

The VOAnews report stated that, “In 2007, Dr. Steven Nissen published a study showing that those taking Avandia had a 43 percent higher risk of having a heart attack and a 64 percent greater chance of dying from a heart attack than those not taking the drug. ‘We’ve been warning about this for two and a half years,’ he said. ‘There really isn’t a good reason for physicians to continue to prescribe the drug. It’s time to get it off the market.’”

Dr. Yasser Ousman at Washington Hospital Center disagrees. Ousman is quoted by VOA as saying, “There are a number of drugs that have been tested in these individuals and Avandia is one of them, and actually, it is quite effective in improving the blood sugar, in normalizing the blood sugar or delaying the occurrence of diabetes in these individuals.”

Ousman further suggests, “If you look at the large studies, that were published over the last several years, including a large number of patients comparing Avandia to a placebo or other drugs, there was actually no increase in that risk.  That risk was based on smaller studies.”

Basing his findings on more than 40 clinical trials, Nissen said, “What bothers me the most is that every month that goes by, more people are harmed by a drug that people simply don’t need.”

The Food and Drug Administration have planned further review of the drug in July, but has cautioned against the discontinued use of Avandia without the advise of your primary health care provider.

The case against GlaxoSmithCline in California has to do with what is claimed as false advertising. There is the suggestion that the drug manufacturer knew the drug could cause heart issues long before they ever issued any warnings that this could be a side effect of using the medication. A Senate report even suggests that the FDA may bear some responsibility in the lack of information passed on to patients.

The VOAnews article further indicates, “A study on Avandia funded by GlaxoSmithKline published last year, found no increase in heart attacks. But it found a significant increase in the risk of heart failure where the heart cannot pump enough blood to the organs or muscles. A number of cases resulted in hospitalization or death.”

Law.com states that Santa Clara County in California “Wants the company to pay back money from all sales of Avandia in California since 1999, as well as pay restitution for medical treatment provided to Avandia users who suffered heart problems.” The county has spent around $2 million on the purchase of Avandia as part of it’s own health program over the years. The lawsuit may have been precipitated by the fact that Santa Clara County has a public hospital and the County is seeking to make decisions in the best interest of their municipal health care facility as well as the patients who use their hospital.

Medicare’s Conditional Approval: Bariatric Surgery

Bariatric surgery is commonly referred to as either Lap-Band surgery or weight loss surgery. The premise behind this surgery is to help patients achieve positive weight loss by effectively reducing the size of their stomach. The smaller space means less food can comfortably be consumed in a single setting. The reduced caloric intake results in weight loss that the patient is better able to keep off.

Bariatric surgery is commonly referred to as either Lap-Band surgery or weight loss surgery. The premise behind this surgery is to help patients achieve positive weight loss by effectively reducing the size of their stomach. The smaller space means less food can comfortably be consumed in a single setting. The reduced caloric intake results in weight loss that the patient is better able to keep off.

Compelling Data
In 2004 the Journal of American Medical Association reported that of more than 22,000 diabetics who received bariatric surgery 76.8 percent of those patients found their diabetes, “Completely resolved.” Other studies seem to point to the possibility that this type of surgery remains a viable contender for management or reversal of diabetes.

Dr. Christine Ren is quoted as saying, “If you lose weight, your diabetes will go away, and when you regain the weight, the diabetes will come back. Diabetes is always lurking, and remission lasts as long as the weight loss lasts.”

Medicare’s Revised Decision
This idea may be why Medicare has revised policies dealing with this procedure. The Centers for Medicare & Medicaid Services (CMS) announced revisions to Medicare in mid February that essentially allow bariatric surgery to be considered for morbidly obese patients who are on Medicare.

HealthNewsDigest indicates, “The decision specifies type 2 diabetes as one of the co-morbidities CMS would consider in determining whether bariatric surgery would be covered for a Medicare beneficiary who is morbidly obese, as long as the surgery is furnished at a CMS-approved facility. An individual with a body-mass index (BMI) of at least 35 is considered morbidly obese. Normal body-mass index is considered to be between 18.5 and 25.”

In explaining the decision CMS Acting Administrator Charlene Frizzera said, “Today’s coverage decision assures that beneficiaries who are morbidly obese can access safe, effective weight loss options to help prevent complications.”

Not For Everyone?
To be clear this procedure can only be considered when Medicare patients have a BMI of 35 or higher. A BMI lower than 35 will not be considered for treatment using this type of surgery.

Surgery Types
This surgical procedure qualifies due to what is referred to as co-morbidity. This essentially means the combination of diabetes and obesity. They both need to be present to qualify. The Health and Human Services website states, “The evidence is adequate to conclude that open and laparoscopic Roux-en-Y gastric bypass (RYGBP), laparoscopic adjustable gastric banding (LAGB), and open and laparoscopic biliopancreatic diversion with duodenal switch (BPD/DS) improve health outcomes in Medicare beneficiaries who have T2DM and a BMI > 35.”

You will notice there are three separate bariatric surgical procedures listed above that could be used to help qualified patients. You should also know that these surgeries need to take place in a Centers for Medicare and Medicaid Services approved facility.

Cost Effective and Diabetic Friendly
It is believed that this procedure may be more cost effective for health treatment among the morbidly obese. Diabetic treatments can be as high as $33,000 annually. If a bariatric surgery successfully reverses diabetes it will actually cost significantly less in the long run while providing a greater quality of life for the patient.

As of this report medical science is still unsure why this type of surgery works. The general consensus is that if they can learn why the procedure is successful there may come a time when they can duplicate the end result with non-surgical options.

Medicare Donut Holes and Nutrisystem’s Large Donation

Medical care is an important consideration for most Americans, but when the costs rise to unmanageable levels there are difficult choices that must be made. In the case of some Medicare patients who also have diabetes it seems to mean a suspension of medication used to control the disease.

Medicare Donut Holes and Nutrisystem’s Large DonationMedical care is an important consideration for most Americans, but when the costs rise to unmanageable levels there are difficult choices that must be made. In the case of some Medicare patients who also have diabetes it seems to mean a suspension of medication used to control the disease.

According to new research Medicare’s Part D prescription drug plan places a central gap in coverage that has resulted in many diabetics forfeiting medication in favor of using the funds to manage other financial obligations.

The cap on the plan is $2,250, but most diabetics go over that amount in medication for their personal care. The patient then must spend $3600 out of pocket before Medicare prescription coverage kicks in again for the calendar year. Some refer to this clause as a ‘donut hole’. There is coverage before and after, but nothing in the middle.

It is clear the primary reason the plan was designed this way was to appeal to prescription drug users to use only medication essential to their care. While this may have been the intent there appear to be more and more diabetics who are simply doing without when the Medicare funds are shut off.

Many of these individuals are living with decisions between diabetic medications and home heating, diabetic medication and transportation or even diabetic medication and food.

There are gap coverage policies and even prescription drug plans designed to lower overall medication costs. They are helping a little, but not as much as some patients need.

Many are hopeful that this disparity can be addressed and revised so that managed care among those on Medicare can result in a quality of life that is an improvement over current conditions.

Meanwhile Nutrisystem will donate up to $350,000 to the American Diabetes Association (ADA) to assist in the “Stop Diabetes” movement.

Nutrisystem is a weight loss company that uses food choices as a means of assisting in personal weight reduction. They have also developed a line of food specifically for diabetics called Nutrisystem-D. It is the potential proceeds from this product that the company will use to assist the ADA. The company has promised $250,000, but the actual amount could be higher based on the success of the Nutrisystem-D product line.

diabetic live is not necessarily endorsing the Nutrisystem-D product line. We are simply reporting what one company is doing to help foster understanding in diabetes and provide assistance in eliminating the disease.

These two stories do serve to indicate that the responsibility for diabetes care has become an important consideration for many. Drug manufacturers are working to provide lower costs, the ADA continues to look for answers and corporations are seeking to find ways to partner with organizations in an effort to eradicate the disease to the degree they can.

Education will always be a primary tool used to confront this disease and used to implement new strategies, reduce incidence of the disease and accessed to make better health decisions early in life.

Diabetes is a silent killer, but one that can be avoided or managed if taken seriously and responded to early.

diabetic live is a committed resource in information and news related to all aspects of diabetes. We are not focused only on one type of the disease and we will share information related to medical advances as well as more natural approaches that have proven successful.

Diabetes and Medicare: Donut Hole Elimination

In an effort to close the legendary ‘donut hole” gap in Medicare Part D coverage the government is sending out $250 checks to hundreds of thousands of Medicare recipients who require prescription medications. The intent is to close the gap in coverage by 2012.

In explaining the donut hole it is important to know there are strong benefits for Medicare users up to $2,830. There is also strong coverage once total prescription amount exceeds $6,440. It is the middle area for which the term “Donut Hole” applies.

There are nearly 28 million Americans enrolled in Medicare Part D coverage and have survived in gap coverage by either paying a substantial amount of out of pocket expenses related to prescription drugs or by simply refusing to refill prescriptions when the benefits ran out. The later can place the individual at risk and cause additional stress and health issues to develop.

Over a fourth of all Medicare Part D users reach the $2,830 prescription level and are left to consider how to fund the more than $3,500 it takes before any additional help is provided. That being said there are plans to effectively eliminate the donut hole.

AmericanProgress.org reports, “Beginning in 2011, Part D beneficiaries who reach the doughnut hole will get a 50 percent discount. This will be phased up to a 75 percent discount on brand name drugs by 2020 and a 7 percent discount on generic drugs—bringing costs to Part D beneficiaries back down to 25 percent (standard coverage level), thereby effectively closing the doughnut hole.”

In the meantime the government continues to send out checks worth $250 to Medicare Part D participants who reach the lower threshold of the ‘donut hole’ with a situational review every quarter. This means that if you reach the threshold in the 3rd quarter you would still be eligible to receive one $250 rebate once that threshold is exceeded.

Perhaps what is most troubling to those observing the program is the disconnect that occurs when Medicare patients reach the threshold and then determine they simply can’t afford to continue the treatment their primary health care provider recommends. By standardizing the subsidy the stress of that donut hole gap is reduced. The perceived end suggests a greater continuance of coverage and an overall improved health outlook for those using this Medicare plan.

For diabetics it is important to note that one in ten Medicare Part D participants will stop taking their diabetes medications once they reach the donut hole threshold. Interestingly 85% of all Medicare Part D participants exceeded the lower threshold, but did not reach the $6,440 level where assistance was once again provided. This means that living in the ‘donut hole’ requires enormous out of pocket expenses for participants.

Only 20% of Medicare Part D providers offer any kind of gap coverage. This leaves an incredibly large remainder to struggle with paying for their prescription needs.

The elimination of the gap is all part of the current Health Care Reform Act. President Obama has said that there will be approximately 4 million Part D beneficiaries that will receive the $250 rebate checks by years end.

While this doesn’t completely eliminate the disparity between the two thresholds many see it as a signal that Medicare will be helping more individuals cope as the Health Care overhaul comes into its own.

Medicare and the Diabetic: Part C

In this article we will review the comprehensive Medicare plan known as Part C. This fee based service covers other Medicare Plans and may be preferred by some Medicare recipients.

In this article we will review the comprehensive Medicare Advantage Plan known as Part C. This fee based service covers other Medicare Plans and may be preferred by some Medicare recipients.

According to Medicare, “Medicare Advantage Plans, sometimes called “Part C” or “MA Plans,” are health plans offered by private companies approved by Medicare. If you join a Medicare Advantage Plan, the plan provides all your Part A (Hospital Insurance) and Part B (Medical Insurance) coverage.

“Medicare Advantage plans always cover emergency and urgent care. Medicare Advantage Plans must cover all the services that Original Medicare covers, except hospice care. (Original Medicare covers hospice care even if you’re in a Medicare Advantage Plan.)

“Medicare Advantage Plans may offer extra coverage, such as vision, hearing, dental, and/or health and wellness programs. Most plans also include Medicare prescription drug coverage.

“Medicare Advantage Plans must follow rules set by Medicare. However, each plan can charge different out-of-pocket costs and have different rules for how you get services (like whether you need a referral to see a specialist or if you have to go to only doctors, facilities, or suppliers that belong to the plan).

“You usually pay one monthly premium to the Medicare Advantage plan, in addition to your Part B premium.

Different Types of Medicare Advantage Plans

  • Health Maintenance Organization (HMO) Plans
  • Preferred Provider Organization (PPO) Plans
  • Private Fee-for-Service (PFFS) Plans
  • Medical Savings Account (MSA) Plans
  • Special Needs Plans (SNP)

Other less common types of Medicare Advantage Plans include:

  • Point of Service (POS) Plans—Similar to HMOs, but you may be able to get some services out-of-network for a higher cost.
  • Provider Sponsored Organizations (PSOs)—Plans run by a provider or group of providers. In a PSO, you usually get your health care from the providers who are part of the plan.

What You Pay in a Medicare Advantage Plan
Your out-of-pocket costs in a Medicare Advantage Plan depend on:

  • Whether the plan charges a monthly premium in addition to your Part B premium.
  • Whether the plan pays any of the monthly Part B premium. Some plans offer this option, usually for an extra cost.
  • Whether the plan has a yearly deductible or any additional deductibles.
  • How much you pay for each visit or service (co-payments).
  • The type of health care services you need and how often you get them.
  • Whether you follow the plan’s rules, like using network providers.
  • Whether you need extra coverage and what the plan charges for it.
  • Whether the plan has a yearly limit on your out-of-pocket costs for all medical services.

How to Join a Medicare Advantage Plan
Not all Medicare Advantage Plans work the same way, so before you join, find out the plan’s rules, what your costs will be, and whether the plan will meet your needs.

More about Medicare Advantage Plans

  • As with Original Medicare, you still have Medicare rights and protections, including the right to appeal.
  • Check with the plan before you get a service to find out whether they will cover the service and what your costs may be.
  • You must follow plan rules, like getting a referral to see a specialist or getting prior approval for certain procedures to avoid higher costs. Check with the plan.
  • You can join a Medicare Advantage Plan even if you have a pre-existing condition, except for End-Stage Renal Disease.
  • You can only join a plan at certain times during the year. In most cases, you’re enrolled in a plan for a year.
  • If you go to a doctor, facility, or supplier that doesn’t belong to the plan, your services may not be covered, or your costs could be higher.
  • If the plan decides to stop participating in Medicare, you‘ll have to join another Medicare health plan or return to Original Medicare. (Source: Medicare)

Islet Cell Transplantation

Type 1 diabetes is a very serious disorder that impacts the day to day existence of the people that suffer from it. While there are many effective treatment options for type 1
diabetes there is still no cure. While there are several potential technologies on the horizon that promise to lessen or even eliminate the worst effects of the disease, such
as the closed loop insulin pump (sometimes inaccurately called an artificial pancreas) and pancreas transfers, the technology that holds the most promise is the islet cell
transplant.

Islet Cell Transplantation: Type 1 diabetes is a very serious disorder that impacts the day to day existence of the people that suffer from it. While there are many effective treatment options for type 1 diabetes there is still no cure. While there are several potential technologies on the horizon that promise to lessen or even eliminate the worst effects of the disease, such as the closed loop insulin pump (sometimes inaccurately called an artificial pancreas) and pancreas transfers, the technology that holds the most promise is the islet cell transplant.

The Islets of Langerhans are microscopic bodies in the pancreas that are responsible for creating and secreting a number of important enzymes, the most well known of which is insulin. These bodies are what fail in a diabetic. In type 2 diabetes, they may produce insulin in smaller amounts than what are necessary (this is not always true–there are also other causes of type 2 diabetes) and they fail altogether in the much more serious type 1 diabetes. Type 1 diabetics must monitor their blood glucose levels many times and day and add insulin as needed, typically through injections or an insulin pump.

There are several types of cells in the Islets of Langerhans. The beta cells are responsible for the production of insulin. The hope for Islet cell transplant is that the beta cells from the donor will become active in the recipient’s pancreas and begin to produce and secrete insulin in the new host. This technique has been successful in limited testing–if it can be refined and made available to a much wider audience, it will be the elusive cure for diabetes that have been sought for years. While testing is in its very early stages, some of the published results have been promising indeed. Many of the recipients have gone for a year or more without having to take a single supplemental dose of insulin. The tests are underway and hopefully the future will hold many more such promising results.

One of the real hurdles that must be overcome before islet cell transplants can be made a viable option for many sufferers of type 1 diabetes is the problem of rejection. Every cell in a human body is covered with unique markers that indicate that the cell is native to the body and not an outside pathogen. Cells that do not contain these individual specific markers are attacked by the immune system which treats them as invaders. With any kind of transplant, the problem of rejection is a very real issue. Since the transplanted cells will have different markers, the immune system will attempt to destroy them since they appear to be outsiders (indeed, they are). The only way to currently prevent rejection is to use medications that decrease the activity of the immune system. This clearly has drawbacks. First, we need our immune systems function properly to keep us health. Those who have a decreased immune system are likely to suffer from a wide range of problems, including frequent cold and flu infections, a high occurrence of mouth and stomach ulcers, higher rates of general infections, etc. The complications that accompany rejection suppression will mean that islet transplant surgery will only be appropriate for those whose diabetes symptoms are worse than the side effects that they will incur because of the required immunosuppressive therapy.

Another problem with the current state of islet transplants is that there simply are not enough donors available to meet the needs of even a small percentage of all type 1 diabetics. Since there will surely be overwhelming demand for the procedure once some of the details are worked out, scientists are currently investigating ways to artificially produce functional islet cells.

Pancreatic Islets

Almost 80 years ago, Dr. Frederick Banting published a report about use of pancreatic Islets to treat diabetes. He obtained those Islets from the pancreas of a dog. By first tying-off that pancreas, he eliminated the digestive enzymes that would otherwise have destroyed the insulin in the Islets.

Pancreatic Islets: Almost 80 years ago, Dr. Frederick Banting published a report about use of pancreatic Islets to treat diabetes. He obtained those Islets from the pancreas of a dog. By first tying-off that pancreas, he eliminated the digestive enzymes that would otherwise have destroyed the insulin in the Islets.

Following the publication of that report, diabetics could hope for a way to replace the insulin lacking in their system. Biochemists were able to extract insulin from the pancreas of an animal. That insulin could then be prepared for injection into a diabetic patient. At that time, doctors could only dream about transplanting Islet cells into a diabetic patient.

Doctors have since learned that the Islets contain several types of cells. Among those various Islets cells, only the beta cells have the ability to make insulin. In the 1970s, a group of medical researchers began to look for a way to transplant beta cells into diabetic patients. Gradually, their research produced significant results.

Dr. Bernard Hering at the University of Minnesota transplanted Islets cells from pigs into monkeys. He published a report about that transplantation in Nature Magazine. Then in June of 2000, the world of medicine learned about a more advanced type of Islet transplantation. Doctors at the University of Alberto in Edmonton, Canada had transplanted Islets cells into human diabetic patients.

The Canadian doctors published the details of their transplantation in The New England Journal of Medicine. They followed that initial report with other reports about the ability of the transplanted Islets to maintain production of insulin. Those follow-up reports indicated that 10% of the 65 patients given the transplanted Islets remained free of a need for insulin five years later (in 2005).

The follow-up report included some other important information. A number of the patients who had received the transplanted Islets found that even though they later needed to receive insulin, they did not need as much insulin as they had prior to the transplantation. Moreover, those patients who had to resume their use of insulin found that after the transplantation they were able to maintain a more stable glucose level.

Among the patients who had received the transplanted Islets, doctors observed something that related to another problem, a problem that challenges many diabetics. Often a patient with diabetes develops what is known as “hypoglycemia unawareness.” When a diabetic develops that condition, he or she can not detect evidence that his or her body needs sugar. Symptoms of “hypoglycemia unawareness” declined among those patients who had received the transplanted Islets.

After medical doctors learned about the results of the Canadian experiment, they studied carefully the procedures used by those Canadian doctors. A number of doctors wanted to replicate the experiment conducted at the University of Alberto. Doctors who hoped to repeat that experiment learned that they needed to follow the following procedure.

The Canadian doctors had taken Islets cells from deceased organ donors. They had prevented destruction of the beta cells by using special enzymes during the removal of the Islets cells. They had then purified and processed those beta cells. Those purified and processed cells were given to a radiologist.

The radiologist used both X-rays and ultra sound to guide a plastic tube through the upper abdomen of the patient who was to receive the transplanted Islet cells. Once safely through the abdomen of that patient, the plastic tube was inserted in the patient’s portal vein (a vein from the liver). The radiologist then infused the Islets cells into the tranquilized patient.

The radiologist did not infuse just a couple cells into each patient. Doctors had determined the number of Islets “equivalents” needed by each patient who was supposed to get some transplanted Islets cells. The doctors had based their determination on the patient’s body weight. The Canadian doctors had found that a diabetic needs 10,000 Islets “equivalents” for every kilogram in his or her body weight.

Following the performance of such a procedure, doctors could expect the transplanted Islets cells to produce insulin for a at least 14 days. There were, as shown by the data in the published report, some patients who produced insulin for far longer than that short, 14 day period. Doctors have initiated a look at ways to refine the procedure used in Canada.

One refinement that has been presented to some medical professionals employs changes in the nature of the material infused into the patient. Doctors who tested this particular refinement put a special coating on the processed and infused Islet cells. Patients who received an infusion of Islets cells with the new coating experienced fewer side effects.

Prior to introduction of this new refinement, some patients had complained about mouth sores, GI problems, and increased infections. The physicians treating the patients with the Islets transplants had seen increases in the patients’ blood pressure and blood cholesterol. None of those side effects could be found among patients who got Islets cells with the new type of coating.

While some medical researchers have focused on delivery of the infused Islet cells, others have looked at how to improve patients’ acceptance of those cells. As in any transplantation, the transplantation of Islet cells demands the use of immunosuppressive drugs. Those drugs put limits on the body’s natural tendency to attack any foreign material within the body.

The Canadian doctors did not rely on the conventional immunosuppressive drugs when doing their Islets cells transplants. They used new drugs, drugs that proved able to enhance the patients’ acceptance of the transplanted cells. They administered those drugs according to a carefully selected pattern.

One drug, doclimszumab, was given to each patient by IV. The patient received that drug immediately after completion of the transplantation. The administration of that drug was brief; the patient did not need to be hooked to the IV for a lengthy amount of time.

Upon discontinuation of the doclimszumab, the patient received two other immunosuppressive drugs—sirulimus and tociclimus. The patient needed to continue taking those drugs for as long as the transplanted Islets cells produced a satisfactory amount of insulin.

An Overview Of Insulin Pumps

Insulin pumps are devices that are used to deliver a measured dose of insulin subcutaneously before or after meals or whenever blood sugar levels become too high. Insulin pumps are much more flexible than insulin injection methods and can help prevent many of the long term diabetes side effects that can occur when insulin is administered at less well metered doses. This article provides an overview of the technology and proper use of insulin pumps and also looks at some insulin pumping technology that is right around the corner that will make controlling insulin levels easier than ever before.

An Overview Of Insulin PumpsInsulin pumps are devices that are used to deliver a measured dose of insulin subcutaneously before or after meals or whenever blood sugar levels become too high. Insulin pumps are much more flexible than insulin injection methods and can help prevent many of the long term diabetes side effects that can occur when insulin is administered at less well metered doses. This article provides an overview of the technology and proper use of insulin pumps and also looks at some insulin pumping technology that is right around the corner that will make controlling insulin levels easier than ever before.

Insulin pumps use a small catheter that is placed under the skin to deliver doses of insulin as needed. Insulin pumps are typically programmed to deliver three different doses of insulin. The first is delivered continuously to meet the insulin needs of continuous metabolism. The second type of insulin delivery is a bolus delivery to cover the carbohydrates that are consumed in a meal or a snack. Most insulin pumps have buttons that will allow you to adjust the amount of insulin added based on the amount of carbohydrates in the meal or snack. Finally, insulin pumps also allow you to administer corrective doses of insulin in case the amount of insulin in the basal and bolus doses did not meet all of your insulin requirements.

Many people think that wearing an insulin pump can make it impossible to do vigorous tasks such as playing sports or jogging. This is not the case. When playing vigorous sports, you can use sturdy elastic to attach the insulin pump to your arm or chest where it should be quite secure. If you are playing an extremely physical sport such as football or rugby, it may be necessary to remove the insulin pump for the duration of the activity. If you must do this, be sure to take an extra bolus dose of insulin to make up for the basal activity that you missed during the event.

Clearly, in order to take advantage of all that insulin pumps have to offer, you have to know how to calculate and control the amount of insulin needed. The first step is to measure the amount of insulin that you use on an average day. It is best to take an average of multiple days in order to get the best approximate dose for a typical level of daily need. Once you have come up with a solid average figure, you need to divide the total dosage into basal and bolus amounts (typically forty to fifty percent for basal and fifty to sixty percent for bolus insulin). Next, you must divide the basal insulin dosage by twenty four to determine you hourly basal insulin requirements. This is the number that you will program into the insulin pump, plus any corrections that you must make for activity or for your individual metabolism.

While modern insulin pumps are a great way to ensure that your insulin is administered at highly metered doses and to keep basal rates consistent, it can still be a pain to continuously program and reprogram the pump. So called “closed loop” insulin pumps are currently in development that will allow continuously monitor blood glucose levels and supply insulin “on demand” as glucose levels fluctuate. This would remove the need for external glucose measurements (except perhaps occasional measurements to verify that the closed loop pump is operating properly). In many ways, this will constitute a replacement pancreas, and will remove many of the manual steps involved in using insulin pumps. These devices are still in development and testing, but they may one day revolutionize the treatment of diabetes.

Secret Link